Table 1:

Summary of group characteristics^{^a}

Characteristic	Gadobenate-Exposed (n = 34)	GBCA-Naïve Control (n = 24)	P Value
Age	7.18 ± 5.93 yr	8.78 ± 5.78 yr	.31
Age	9 mo to 17 yr	7 mo to 17 yr	.31
Sex (M/F)	17:17	16:8	.28
Body weight (kg)	30.55 ± 18.57	26.71 ± 17.23	.43
Body weight (kg)	7.8–68	8.1–64	.43
No. of administrations	7.8 ± 2.9	NA	NA
No. of administrations	5–15	NA	NA
Interval between first and last administrations	2.24 ± 1.97 yr	NA	NA
Interval between first and last administrations	9 mo to 7 yr	NA	NA
Accumulated volume of gadobenate administered (mL)	29.35 ± 24.95	NA	NA
Accumulated volume of gadobenate administered (mL)	5–112	NA	NA
Accumulated gadobenate dose (g)^{^b}	9.8 ± 8.33	NA	NA
Accumulated gadobenate dose (g)^{^b}	1.67–37.41	NA	NA

Note:—NA indicates not applicable.
↵a Data are mean ± SD and range.
↵b One milliliter of MultiHance solution for injection contains 334 mg of gadobenic acid as the meglumine salt.³⁹